INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is a major public health problem, with major impact on morbidity and mortality. It is the second most prevalent malignancy worldwide, and is also second in incidence and mortality in most developed countries. In Europe, five-year survival rates are 44-64%, and in Spain the EUROCARE-4 project calculated a survival rate of 61.5% \[[@R1]\]. As a result of population aging, together with diagnostic and therapeutic advances, the number of cancer patients has increased significantly, and this situation is placing great pressure on the cancer care system, reflecting the growing importance of this group of diseases as a public health problem.

Early diagnosis of cancer and hence early treatment is a fundamental objective in cancer care procedures. Although delays attributable to the health system constitute a small proportion of the biological life of a tumour, noticeable hospital delay (from first hospital visit to diagnosis or from diagnosis to treatment) may provoke stress and decrease the patient\'s quality of life. In fact, delays in initiating treatment are the leading cause of malpractice complaints \[[@R2]\].

While some studies indicate that treatment delay negatively affects the prognosis of patients with cancer, particularly CRC, others have found no such association \[[@R3], [@R4]\]. Moreover, it has been reported that delay is often attributable to tumour factors such as clinical stage and location, and not only to the health system, such as hospital admission procedures. The impact of treatment delay on survival, and the significance of the diverse factors involved, have yet to be determined \[[@R5]\]. Waiting time is a complex variable, which can reflect the patient\'s own behaviour, the clinical course, the functioning of the health system and tumour biology \[[@R6]\].

Taking into account the dearth of prospective studies designed to analyse treatment delay, with large cohorts of patients and distinguishing between colonic and rectal tumours, in this study we evaluate the degree to which treatment delay is influenced by the sociodemographic conditions of patients and by the clinical and pathological characteristics of the tumour.

RESULTS {#s2}
=======

Descriptive analysis {#s2_1}
--------------------

During the recruitment period, the 22 participating centres recruited 2,749 patients who met the criteria for inclusion. Of these, 330 (12%) were later excluded from the study because it was not possible to determine the treatment delay. Thus, the final patient sample was composed of 2,419 records. The sociodemographic and clinicopathological characteristics of the study population are shown in Table [1](#T1){ref-type="table"}.

###### Sociodemographic and clinical characteristics for all cases and segmented by type of tumour

                                           Total    Colon     Rectal   *p*                          
  ---------------------------------------- -------- --------- -------- --------- -------- --------- ---------------
  **Sex**                                                                                           
    Male                                   1539     63.6      1092     62.2      447      67.3      ***0.023***
    Female                                 880      36.4      663      37.8      217      32.7      
  **Age**                                                                                           
    *Mean - SD*                            *68.3*   ±*10.9*   *68.8*   ±*10.8*   *66.9*   ±*11.0*   ***\<0.001***
  **Marital status^1^**                                                                             
    Single                                 150      7.6       100      6.9       50       9.1       ***0.048***
    Married-Cohabiting                     1434     72.2      1028     71.4      406      74.2      
    Separated-Divorced                     100      5.0       76       5.3       24       4.4       
    Widowed                                302      15.2      235      16.3      67       12.2      
  **Education profile^2^**                                                                          
    No education-Primary education         1531     77.2      1114     77.1      417      77.2      *1.000*
    Secondary-University                   453      22.8      330      22.9      123      22.8      
  **Currently in work^3^**                                                                          
    No                                     1493     76.3      1072     75.3      421      78.7      *0.135*
    Yes                                    465      23.7      351      24.7      114      21.3      
  **BMI^4^**                                                                                        
    *Mean - SD*                            *27.7*   ±*4.8*    *28.0*   ±*4.9*    *27.1*   ±*4.5*    ***\<0.001***
  **Smoking habit^5^**                                                                              
    Never                                  1109     47.8      831      49.6      278      43.3      ***0.008***
    Current smoker                         302      13.0      201      12.0      101      15.7      
    Ex-smoker                              908      39.2      645      38.5      263      41.0      
  **Family history of neoplasias^6^**                                                               
    No                                     1339     61.3      990      63.1      349      56.7      ***0.007***
    Yes                                    846      38.7      580      36.9      266      43.3      
  **Family history of CRC^7^**                                                                      
    No                                     1295     86.2      934      86.3      361      85.7      *0.837*
    Yes                                    208      13.8      148      13.7      60       14.3      
  **Specific signs and symptoms^8^**                                                                
    Asymptomatic                           204      8.8       160      9.6       44       6.9       ***\<0.001***
    Moderate signs and symptoms            381      16.5      300      18.0      81       12.6      
    Severe signs and symptoms              1724     74.7      1207     72.4      517      80.5      
  **Type of tumour**                                                                                
    Colon                                  1755     72.6                                            
    Recto                                  664      27.4                                            
  **Size of tumour^9^**                                                                             
    Locally small (T0-T1-T2)               681      28.8      376      21.9      305      47.0      ***\<0.001***
    Locally large (T3-T4)                  1686     71.2      1342     78.1      344      53.0      
  **Lymph nodes^10^**                                                                               
    Absent                                 1464     62.7      1028     60.0      436      70.1      ***\<0.001***
    Present                                871      37.3      685      40.0      186      29.9      
  **Histological diagnosis^11^**                                                                    
    Adenocarcinoma                         2152     89.6      1555     89.0      597      91.3      *0.121*
    Mucinous carcinoma or other types      249      10.4      192      11.0      57       8.7       
  **Metastasis^12^**                                                                                
    Absent                                 2057     91.9      1483     91.2      574      93.8      *0.056*
    Present                                181      8.1       143      8.8       38       6.2       
  **Differentiation^13^**                                                                           
    Low grade                              1790     86.9      1333     86.4      457      88.2      *0.336*
    High grade                             270      13.1      209      13.6      61       11.8      
  **Vascular invasion^14^**                                                                         
    Absent                                 1764     86.4      1259     84.4      505      92.0      ***\<0.001***
    Present                                277      13.6      233      15.6      44       8.0       
  **Perineural invasion^15^**                                                                       
    Absent                                 1627     81.4      1165     80.1      462      84.8      **0.019**
    Present                                373      18.7      290      19.9      83       15.2      
  **Carcinoembryonic antigen (CEA)^16^**                                                            
    Normal (0-5)                           1328     68.7      917      67.5      411      71.6      *0.083*
    Abnormal (\>5)                         605      31.3      442      32.5      163      28.4      
  **Cancer antigen 19-9^17^**                                                                       
    Normal (1-37)                          944      85.4      620      84.1      324      88.0      *0.099*
    Abnormal (\>37)                        161      14.6      117      15.9      44       12.0      
  **Prior screening^18^**                                                                           
    No                                     1868     80.8      1330     79.1      538      85.4      ***0.001***
    Yes                                    443      19.2      351      20.9      92       14.6      

Losses: 1=433; 2=435; 3=461; 4=552; 5=100; 6=234; 7=916; 8=110.

Losses: 9=52; 10=84; 11=18; 12=181; 13=359; 14=378; 15=419; 16=486; 17=1314; 18=108

Treatment delays and types of treatment {#s2_2}
---------------------------------------

For all tumours, the most common initial treatment was surgery (81.4%), followed by chemotherapy (13%) (p\<0.001). For rectal tumours alone, surgery and chemotherapy were also the most common treatment options (40.5% and 39.5%, respectively).

A histogram showing the distribution of treatment delay is shown in Figure [1](#F1){ref-type="fig"}. A delay to first treatment exceeding 30 days was recorded in 65.5% of cases \[95% CI: 63.6-67.4\], and this value was higher (p\<0.001) for rectal tumours (74.4%) than for colon tumours (62.2%) (Table [2](#T2){ref-type="table"}). Stratifying according to the first mode of treatment administered and by tumour location, there was a higher frequency of delay for surgical treatment for rectal tumours than for colon tumours (79.2% vs. 62.2%) (p\<0.001). No significant differences were observed for the other treatment strategies.

![Frequency histogram of delay (in days) to first treatment for patients with CRC](oncotarget-08-36728-g001){#F1}

###### Type of first treatment and delays

                                  Total   Colon   Rectal   *p*                 
  ------------------------------- ------- ------- -------- ------ ----- ------ ---------------
  **First line of treatment**                                                  
    Surgery                       1968    81.4    1699     96.8   269   40.5   ***\<0.001***
    Chemotherapy^1^               314     13.0    52       3.0    262   39.5   
    Radiotherapy                  137     5.7     4        0.2    133   20.0   
  **Delay in first treatment**                                                 
    ≤30 days                      834     34.5    664      37.8   170   25.6   ***\<0.001***
    \>30 days                     1585    65.5    1091     62.2   494   74.4   
  **Delay before surgery**                                                     
    ≤30 days                      699     35.5    643      37.8   56    20.8   ***\<0.001***
    \>30 days                     1269    64.5    1056     62.2   213   79.2   
  **Delay before chemotherapy**                                                
    ≤30 days                      96      30.6    20       38.5   76    29.0   *0.235*
    \>30 days                     218     69.4    32       61.5   186   71.0   
  **Delay before radiotherapy**                                                
    ≤30 days                      39      28.5    1        25.0   38    28.6   *1.000*
    \>30 days                     98      71.5    3        75.0   95    71.4   

^1^ With or without radiotherapy

Relation between treatment delay and the patients' sociodemographic and clinicopathological characteristics {#s2_3}
-----------------------------------------------------------------------------------------------------------

In our analysis of the relation between the presence of DFT and each of the sociodemographic variables, those that were significantly associated with greater DFT in patients with cancer of the colon were male sex, low level of education or no formal education, BMI (28±5.1), ex-smoker and asymptomatic at diagnosis. The most relevant tumour characteristics were small local extension and the absence of nodes, of metastasis and of perineural invasion. Treatment delays in patients with tumours presenting normal values for carcinoembryonic antigen and for cancer antigen 19-9 were greater than among patients presenting abnormal values for these parameters. Finally, the treatment delay in patients who had received prior screening was greater than among those who had not had this test (Table [3](#T3){ref-type="table"}). For rectal tumours, the variables that were significantly related to a higher level of DFT were primary studies or no formal education, being asymptomatic and having had prior screening (Table [4](#T4){ref-type="table"}).

###### Bivariate and multivariate analysis with DFT in patients with colon cancer

                                       ≤30 days   \>30 days   *Crude analysis*   *Adjusted analysis*\*                                                              
  ------------------------------------ ---------- ----------- ------------------ ----------------------- --------------- -------------------------- --------------- -------------------------
  **Sex**                                                                                                                                                           
    Male                               393        36.0        699                64.0                    ***0.041***     ***1.00***                                 
    Female                             271        40.9        392                59.1                                    ***0.81 \[0.67-0.99\]***                   
  **Age**                                                                                                                                                           
    *Mean - SD*                        68.8       ±11.3       68.8               ±10.4                   *0.915*         *1.00 \[0.99-1.01\]*                       
  **Marital status**                                                                                                                                                
    Single                             38         38.0        62                 62.0                    *0.182*         *1.00*                                     
    Married-Cohabiting                 374        36.4        654                63.6                                    *1.07 \[0.70-1.64\]*                       
    Separated-Divorced                 21         27.6        55                 72.4                                    *1.60 \[0.84-3.06\]*                       
    Widowed                            97         41.3        138                58.7                                    *0.87 \[0.54-1.41\]*                       
  **Education profile**                                                                                                                                             
    No education-Primary education     388        34.8        726                65.2                    ***0.001***     *1.00*                     ***0.008***     *1.00*
    Secondary-University               148        44.8        182                55.2                                    ***0.66 \[0.51-0.84\]***                   ***0.69\[0.52-0.91\]***
  **Currently in work**                                                                                                                                             
    No                                 396        36.9        676                63.1                    *0.482*         *1.00*                                     
    Yes                                137        39.0        214                61.0                                    *0.91 \[0.71-1.17\]*                       
  **BMI**                                                                                                                                                           
    *Mean - SD*                        27.2       ±4.4        28.4               ±5.1                    ***\<0.001***   ***1.06 \[1.03-1.08\]***                   
  **Smoking habit**                                                                                                                                                 
    Never                              332        40.0        499                60.0                    ***0.017***     *1.00*                     **0.028**       *1.00*
    Current smoker                     83         41.3        118                58.7                                    *0.95 \[0.69-1.29\]*                       *1.08\[0.74-1.57\]*
    Ex-smoker                          215        33.3        430                66.7                                    ***1.33 \[1.07-1.65\]***                   ***1.40\[1.09-1.80\]***
  **Family history of neoplasias**                                                                                                                                  
    No                                 374        37.8        616                62.2                    *0.952*         *1.00*                                     
    Yes                                220        37.9        360                62.1                                    *0.99\[0.80-1.23\]*                        
  **Family history of CRC**                                                                                                                                         
    No                                 323        34.6        611                65.4                    *0.212*         *1.00*                                     
    Yes                                59         39.9        89                 60.1                                    *0.80\[0.56-1.14\]*                        
  **Specific signs and symptoms**                                                                                                                                   
    Asymptomatic                       40         25.0        120                75.0                    ***\<0.001***   1.00                                       
    Moderate signs and symptoms        132        44.0        168                56.0                                    ***0.42\[0.28-0.65\]***                    
    Severe signs and symptoms          466        38.6        741                61.4                                    ***0.53\[0.36-0.77\]***                    
  **Size of tumour**                                                                                                                                                
    Locally small (T0-T1-T2)           96         25.5        280                74.5                    ***\<0.001***   *1.00*                     ***\<0.001***   *1.00*
    Locally large (T3-T4)              555        41.4        787                58.6                                    ***0.49\[0.37-0.63\]***                    ***0.51\[0.37-0.69\]***
  **Lymph nodes**                                                                                                                                                   
    Absent                             365        35.5        663                64.5                    ***0.015***     *1.00*                                     
    Present                            283        41.3        402                58.7                                    ***0.78\[0.64-0.95\]***                    
  **Histological diagnosis**                                                                                                                                        
    Adenocarcinoma                     585        37.6        970                62.4                    *0.597*         1.00                                       
    Mucinous carcinoma                 76         39.6        116                60.4                                    *0.92\[0.68-1.25\]*                        
  **Metastasis**                                                                                                                                                    
    Absent                             523        35.3        960                64.7                    ***0.037***     1.00                                       
    Present                            63         44.1        80                 55.9                                    **0.69\[0.49-0.98\]**                      
  **Differentiation**                                                                                                                                               
    Low grade                          490        36.8        843                63.2                    *0.223*         1.00                                       
    High grade                         86         41.1        123                58.9                                    0.83\[0.62-1.12\]                          
  **Vascular invasion**                                                                                                                                             
    Absent                             475        37.7        784                62.3                    *0.212*         1.00                                       
    Present                            98         42.1        135                57.9                                    0.83\[0.63-1.11\]                          
  **Perineural invasion**                                                                                                                                           
    Absent                             426        36.6        739                63.4                    ***0.001***     1.00                                       
    Present                            137        47.2        153                52.8                                    **0.64\[0.50-0.83\]**                      
  **Carcinoembryonic antigen (CEA)**                                                                                                                                
    Normal (0-5)                       324        35.3        593                64.7                    ***0.010***     1.00                                       
    Abnormal (\>5)                     188        42.5        254                57.5                                    **0.74\[0.58-0.93\]**                      
  **Cancer antigen 19-9**                                                                                                                                           
    Normal (1-37)                      219        35.3        401                64.7                    ***0.011***     1.00                                       
    Abnormal (\>37)                    56         47.9        61                 52.1                                    **0.59\[0.40-0.89\]**                      
  **Prior screening**                                                                                                                                               
    No                                 547        41.1        783                58.9                    ***\<0.001***   1.00                       ***\<0.001***   1.00
    Yes                                89         25.4        262                74.6                                    **2.06\[1.59-2.68\]**                      **1.79\[1.32-2.43\]**
  **First line of treatment**                                                                                                                                       
    Surgery                            643        37.8        1056               62.2                    *0.869*         1.00                                       
    Chemotherapy                       20         38.5        32                 61.5                                    *0.97\[0.55-1.72\]*                        
    Radiotherapy                       1          25.0        3                  75.0                                    *1.83\[0.19-17.6\]*                        

^\*^ In multivariate logistic regression with a sample of 1,291 patients

###### Bivariate and multivariate analysis with DFT in patients with rectal cancer

                                       ≤30 days   \>30 days   *Crude analysis*   *Adjusted analysis*\*                                                   
  ------------------------------------ ---------- ----------- ------------------ ----------------------- ----------- ----------------------- ----------- -----------------------
  **Sex**                                                                                                                                                
    Male                               109        24.4        338                75.6                    0.303       1.00                                
    Female                             61         28.1        156                71.9                                0.82\[0.57-1.19\]                   
  **Age**                                                                                                                                                
    *Mean - SD*                        65.9       ±11.2       67.2               ±11.0                   0.168       1.01\[0.99-1.03\]                   
  **Marital status**                                                                                                                                     
    Single                             9          18.0        41                 82.0                    0.145       1.00                                
    Married-Cohabiting                 111        27.3        295                72.7                                0.58\[0.27-1.24\]                   
    Separated-Divorced                 2          8.3         22                 91.7                                2.41\[0.48-12.17\]                  
    Widowed                            18         26.9        49                 73.1                                0.60\[0.24-1.47\]                   
  **Education profile**                                                                                                                                  
    No education-Primary education     97         23.3        320                76.7                    **0.025**   1.00                    **0.020**   1.00
    Secondary-University               41         33.3        82                 66.7                                **0.61\[0.39-0.94\]**               **0.56\[0.34-0.91\]**
  **Currently in work**                                                                                                                                  
    No                                 107        25.4        314                74.6                    0.845       1.00                                
    Yes                                30         26.3        84                 73.7                                0.95\[0.60-1.53\]                   
  **BMI**                                                                                                                                                
    *Mean - SD*                        26.9       ±4.1        27.1               ±4.7                    0.699       1.01\[0.96-1.05\]                   
  **Smoking habit**                                                                                                                                      
    Never                              71         25.5        207                74.5                    0.989       1.00                                
    Current smoker                     26         25.7        75                 74.3                                0.99\[0.59-1.67\]                   
    Ex-smoker                          66         25.1        197                74.9                                1.02\[0.69-1.51\]                   
  **Family history of neoplasias**                                                                                                                       
    No                                 88         25.2        261                74.8                    0.757       1.00                                
    Yes                                70         26.3        196                73.7                                0.94\[0.66-1.36\]                   
  **Family history of CRC**                                                                                                                              
    No                                 91         25.2        270                74.8                    0.386       1.00                                
    Yes                                12         20.0        48                 80.0                                1.35\[0.87-2.65\]                   
  **Specific signs and symptoms**                                                                                                                        
    Asymptomatic                       4          9.1         40                 90.9                    **0.009**   1.00                    **0.031**   1.00
    Moderate signs and symptoms        15         18.5        66                 81.5                                0.44\[0.14-1.42\]                   0.67\[0.16-2.74\]
    Severe signs and symptoms          146        28.2        371                71.8                                **0.25(0.09-0.72)**                 0.31\[0.09-1.07\]
  **Size of tumour**                                                                                                                                     
    Locally small (T0-T1-T2)           78         25.6        227                74.4                    0.998       1.00                                
    Locally large (T3-T4)              88         25.6        256                74.4                                1.00\[0.70-1.42\]                   
  **Lymph nodes**                                                                                                                                        
    Absent                             116        26.6        320                73.4                    0.292       1.00                                
    Present                            42         22.6        144                77.4                                1.42\[0.83-1.86\]                   
  **Histological diagnosis**                                                                                                                             
    Adenocarcinoma                     152        25.5        445                74.5                    0.660       1.00                                
    Mucinous carcinoma                 13         22.8        44                 77.2                                1.16\[0.61-2.20\]                   
  **Metastasis**                                                                                                                                         
    Absent                             138        24.0        436                76.0                    0.751       1.00                                
    Present                            10         26.3        28                 73.7                                0.89\[0.42-1.87\]                   
  **Differentiation**                                                                                                                                    
    Low grade                          106        23.2        351                76.8                    0.175       1.00                                
    High grade                         19         31.1        42                 68.9                                0.67\[0.37-1.20\]                   
  **Vascular invasion**                                                                                                                                  
    Absent                             127        25.1        378                74.9                    0.490       1.00                                
    Present                            9          20.5        35                 79.5                                1.31\[0.61-2.79\]                   
  **Perineural invasion**                                                                                                                                
    Absent                             112        24.2        350                75.8                    **0.042**   1.00                    0.051       1.00
    Present                            29         34.9        54                 65.1                                **0.60\[0.36-0.98\]**               0.57\[0.32-1.00\]
  **Carcinoembryonic antigen (CEA)**                                                                                                                     
    Normal (0-5)                       105        25.5        306                74.5                    0.722       1.00                                
    Abnormal (\>5)                     44         27.0        119                73.0                                0.93\[0.61-1.40\]                   
  **Cancer antigen 19-9**                                                                                                                                
    Normal \[[@R1]−37\]                70         21.6        254                78.4                    0.133       1.00                                
    Abnormal \[\>37\]                  14         31.8        30                 68.2                                0.59\[0.30-1.17\]                   
  **Prior screening**                                                                                                                                    
    No                                 148        27.5        390                72.5                    **0.025**   1.00                                
    Yes                                15         16.3        77                 83.7                                **1.95\[1.09-3.49\]**               
  **First line of treatment**                                                                                                                            
    Surgery                            56         20.8        213                79.2                    0.067       1.00                                
    Chemotherapy                       76         29.0        186                71.0                                0.64\[0.43-0.96\]                   
    Radiotherapy                       38         28.6        95                 71.4                                0.66\[0.41-1.06\]                   

^\*^ In multivariate logistic regression with a sample of 433 patients

After adjusting for variables found to be statistically significant in the crude analysis, the multivariate analysis revealed the following to be independent protective factors against increased DFT: having university studies, for colon cancer \[OR = 0.69; 95% CI 0.52-0.91\] and for rectal cancer \[OR = 0.56; 95% CI 0.34-0.91\]; later tumour stage, for colon tumours, T3-T4, \[OR = 0.51; 95% CI 0.37-0.69\]; and for rectal tumours, the presence of severe \[OR = 0.31; 95% CI 0.09-1.07\] or moderate symptoms \[OR = 0.67; 95% CI 0.16-2.74\], compared with asymptomatic patients. However, DFT was greater in the patients with colon cancer who were ex-smokers \[OR = 1.40; 95% CI 1.09-1.80\] and in those who had had prior screening \[OR = 1.79; 95% CI: 1.32-2.43\] (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}).

DISCUSSION {#s3}
==========

Our study highlights the existence of delayed implementation of the first treatment among 65.5% of the population diagnosed with CRC. This finding lies within the 40-70% range of treatment delay previously reported \[[@R7]\].

Studies have been conducted to evaluate the prognostic influence of diagnostic and treatment delays on different types of cancer, and to determine the significant factors in this process. However, conflicting results have been obtained, due in part to differences in the characteristics of the populations analysed; furthermore, in most cases, the cohorts have been examined retrospectively and there have been differences in the time intervals studied \[[@R8]\]. This is a controversial issue, and it remains to be clarified. Unlike these earlier studies, our own research is based on a large number of patients recruited prospectively. We define excessive delay between diagnosis and treatment as a period exceeding 30 days, following previous recommendations and reports in this respect \[[@R9], [@R10], [@R11], [@R12], [@R13]\]

Unlike other studies on diagnostic and treatment delays in patients with CRC, our study population is distributed according to the location of the tumour (colon or rectal), in view of the well-known differences in the pathogenesis of each. We found DFT to be significantly greater for rectal tumours, as was also reported in the case of delay attributable to the patient \[[@R14]\]. Analysis of the delay according to the type of first treatment applied showed that this difference persisted when the first treatment was surgery, but not when it was chemotherapy or radiotherapy. This association is consistent with the findings of other studies, which have related the delay in surgical treatment for advanced stage (according to the Dukes system) rectal tumours, but not for tumours of the colon \[[@R15]\], probably because in localised and locally-advanced rectal tumours, and unlike for colon cancer, other diagnostic tests are required prior to treatment, such as pelvic magnetic resonance imaging and rectal endoscopic ultrasound examination \[[@R16]\]. Another difference between the two types of cancer was the relationship between DFT and the digestive symptoms diagnosed; a shorter DFT was only observed in patients with rectal cancer and moderate to severe symptoms, compared with mildly symptomatic or asymptomatic patients. Possibly the more pronounced and alarming symptoms resulting from rectal tumours, i.e. bleeding and pain, compared to the less specific and subacute ones provoked by colon tumours, lead patients with rectal cancer to seek a medical consultation at an earlier stage, thus expediting the diagnostic-therapeutic circuit. The physician prescribing the treatment will probably give preference to symptomatic patients, who are at increased risk of presenting complications from the tumour and therefore have a worse prognosis. It should also be taken into account that some patients with advanced tumours do not state the actual date of onset of their symptoms, or minimise it, due to a feeling of guilt at not having consulted the doctor sooner, and this too can exacerbate the DFT \[[@R17]--[@R19]\].

Studies of CRC have evaluated the relationship between tumour stage and diagnostic and therapeutic delays, and have found no association between these parameters \[[@R20]\]. Although some studies have shown that the DFT is shorter for patients presenting advanced stages of the disease \[[@R21]\], others have concluded the opposite \[[@R22]\]. Nevertheless, these conclusions cannot be generalised for tumours of the colon and rectum as if they were a single entity; on the contrary, they must be analysed independently, in view of the different natural history presented in each case \[[@R23], [@R24]\]. Thus, some retrospective studies have shown that advanced rectal tumours present an increased risk of DFT, in comparison with the initial stages, while no such differences were found for cancers of the colon \[[@R15]\]. On the other hand, in our own study, tumour stages T1-T2 experienced greater DFT than more advanced stages, but only in tumours of the colon. This difference might arise from the lower priority assigned to treatment for early-stage cancers, when symptoms are usually less apparent and hence delay the start of the therapeutic process. In a study of breast cancer, our group evaluated the different periods of delay, noting that higher tumour stages were associated with a shorter DFT, which was associated with a lower disease-free survival time. This outcome is probably produced by the priority granted by doctors to patients whose symptoms are more severe \[[@R6]\], which contradicts the traditional view that greater delay is associated with decreased survival time. This inverse correlation between treatment delay and survival has been described previously in studies of the endometrium and the lung \[[@R22], [@R25]\].

In our analysis of clinicopathological characteristics with known prognostic value and associated with increased tumour aggressiveness, the degree of histological differentiation and of lymphovascular invasion presented no relation to DFT. However, they were found to be related to distant metastases, lymph node involvement, perineural invasion and elevated tumour markers, all of which decrease the risk of severe DFT. However, when a multivariate analysis was performed, and other variables were taken into account, these differences did not persist, probably because the variables in question are more dependent on the biological behaviour of the tumour and on its intrinsic aggressiveness than on the period of treatment delay, as suggested by Symonds in a study of cervical cancer \[[@R26]\]. In other tumours, such as breast cancer, a significant association has also been described between the presence of more aggressive features and a shorter delay in initiating treatment; such features may include the non expression of hormone receptors, or non response to hormonal treatments in tumours that do express hormone receptors. These findings suggest that treatment may be expedited when the physician is aware of the extent of the tumour \[[@R6]\].

Among the sociocultural factors analysed, the lack of formal education or only having had primary education significantly increases the risk of DFT, for both rectal and colon tumours. Interestingly, this association, which has not received much previous research attention, influences DFT independently of other factors. One explanation for this might be that these patients do not understand the instructions received during the diagnosis-therapy process, and may also fail to keep the medical appointments necessary for a definitive tumour treatment to be undertaken. This population group, with a low cultural level, might also delay the start of treatment for fear of future treatments and distrust of the benefit derived from them. This possibility was raised in a recent study in which DFT was associated with a lack of knowledge of symptoms suggestive of cancer, and with the patient\'s unwillingness to visit the doctor, among other factors \[[@R27]\]. For these reasons, we believe that among certain population groups, with unhealthy living habits and a low educational profile, the risk of severe DFT is greater. In this respect, a retrospective study was conducted to obtain an ecological estimation of the socioeconomic status of patients with cancer (European Deprivation Index). No such relationship with DFT or with diagnostic delay was found, although it should be noted that this study included different types of cancer, with only 116 CRC \[[@R28]\].

Retrospective studies have evaluated social factors that might influence treatment delay, noting that black and/or elderly patients with rectal cancer were subject to greatest delay in initiating adjuvant chemotherapy \[[@R29]\]. In another study, of bowel cancer \[[@R30]\], elderly and/or unmarried patients were found to be most subject to this delay. Other studies evaluating prehospital delay have also found that lower socioeconomic level and lower education level are relevant factors. \[[@R14], [@R31]\].

Another feature of our population which the univariate analysis showed to be associated with increased treatment delay was a high BMI (\>28) in patients with colon cancer. This relation would be explained, in part, by the complication of abdominal examination in the presence of a large pannus. One of the main causes of obesity in the West is an unhealthy living habit in terms of diet and exercise; this, too, is associated with a low socio-cultural level, which as mentioned previously is an independent predictor of treatment delay. The remaining demographic variables analysed--sex, age at diagnosis, family history of cancer, marital status and occupation--bore no significant relation with DFT.

The relationship between treatment delay and ex-smokers is a complex one. Elderly ex-smokers probably have more limitations of the respiratory function and require a larger number of tests before surgery. On the other hand, a patient who gives up smoking will probably believe him/herself at less risk of serious disease than a continuing smoker, and this factor, too, may influence communication with the doctor after diagnosis. In this respect, Mosher et al., in a study of patients diagnosed with lung cancer, reported that most ex-smokers rejected psychological therapy \[[@R32]\].

Our results show that a prior positive screening, in which faecal occult blood is detected, is associated with a greater risk of treatment delay; this relation has not been reported in previous studies. A priori, it seems illogical that a patient who has received CRC screening before any treatment is undertaken should suffer a delay for this reason. However, probably due to the person\'s asymptomatic state at the time of the consultation, no preference is expressed (unlike the case of a patient with manifest symptoms and at increased risk of complications from the tumour, requiring prompt treatment). Nevertheless, we considered the possible existence of confounding and of interaction with the other variables, and always obtained the same relationship between prior screening and subsequent treatment delay. Neither were there any interaction terms to be retained in the final model (data not shown).

Although it has been shown that delayed diagnosis and treatment does not appear to increase the risk of death in patients with symptomatic CRC, among the asymptomatic population early diagnosis and treatment may play a role in reducing morbidity and mortality \[[@R33]\]. The results presented should be considered with caution, and are subject to further analysis to determine whether, in the screened population, the greater delay observed impacts on survival.

The delay before cancer treatment is started is an important factor to be evaluated. This delay, which is a criterion of health care quality, should be prevented and reduced as far as possible in order to avoid the psychologically negative impact it may cause to patients. Numerous studies have shown that treatment delay is associated with certain clinical factors in CRC, but the present study is the first to establish that DFT depends not only on clinicopathological characteristics of the tumour, or on deficiencies of the healthcare system, but also on sociocultural characteristics of the population. We conclude, therefore, that more attention should be paid to health education regarding the initial symptoms related to this disease, especially among less educated social groups. The physician responsible for the patient\'s treatment, too, must be aware that these patients require special attention.

Finally, more multicentre studies should be conducted, in other countries and where different healthcare plans are used, in order to generalise the findings of our study. Another valuable area for future research would be to determine whether treatment delay also impacts on survival, as this association has not been clarified in recent reviews of the question \[[@R6], [@R34]\].

MATERIALS AND METHODS {#s4}
=====================

Study design {#s4_1}
------------

This prospective, multicentre observational study was conducted in coordination with 22 public-sector hospitals in six regions of Spain (Andalusia, Canary Islands, Catalonia, Madrid, Valencia and the Basque Country) \[[@R35]\].

The patients were recruited prospectively and consecutively at each of the participating hospitals between June 2010 and December 2012. The study population included patients diagnosed with new colon or rectum cancer, stage I-IV and surgically treated, whether urgently or scheduled. All patients were included, whether or not they had previously received treatment, and a follow up study of five years was scheduled. Data were compiled directly from patients and also from their medical history.

Study definitions {#s4_2}
-----------------

Excessive treatment delay was defined as an interval exceeding 30 days from pathological diagnosis to first treatment, in accordance with national guidelines and previous reports \[[@R10]--[@R13], [@R15]\]. First treatment was taken to be surgery, chemotherapy, radiotherapy, biological therapy or best supportive care. Date of diagnosis was the date when histological confirmation of the process was obtained, unless this coincided with the date of the intervention. In this case, we used as first date of diagnosis the suspected diagnosis \[[@R35]\].

The anatomical location of the tumour and the histology findings were coded in accordance with the International Classification for Oncology (ICD-O). Staging classification was based on the TNM recommendations of the International Union Against Cancer, 7th edition.

The following inclusion criteria were applied:

-   Patients diagnosed with cancer of the colon (up to 15 cm above the anal margin) or of the rectum (between the anal margin and 15 cm above it), to which curative and/or palliative surgical treatment was applied for the first time.

-   Signed informed consent provided.

The exclusion criteria were:

-   Patients diagnosed with cancer of the colon or rectum in situ.

-   Unresectable tumours.

-   Mental or physical disorders that prevented the patient from answering the questionnaires.

-   Terminal patients

The project was evaluated by the corresponding Research Committees and Clinical Research Ethics Committees at the hospitals. Informed consent was requested of the patients before surgery. Current legislative requirements regarding personal data (any information concerning individuals who were identified or identifiable) were followed at all times. All personal data were processed in such a way that the information obtained could not be associated with identified or identifiable persons (Protection of Personal Data Act, 15/1999, 13-12).

Study variables {#s4_3}
---------------

Data were compiled regarding the patients' medical history: Sex, age, body mass index, prior screening, date of first contact with the hospital, first diagnosis, start of treatment, and the various types of first treatment considered (surgery, chemotherapy, radiotherapy, biological therapy or best supportive care). The date of diagnosis was taken as the date when the first histopathological report identifying the presence of cancer, was issued, except patients treated at the same time as they were diagnosed that we used as first date of diagnosis the suspected diagnosis date. The following laboratory and pathological factors were also recorded: tumour location (rectum or colon), degree of histological differentiation, tumour stage T and lymph node N (determined by the TNM clinical staging system), lymphovascular and perineural invasion, presence of metastasis, status of tumour markers such as carbohydrate antigen (*CA*) *19-9* and serial carcino-embryonic antigen (CEA). \[[@R36]\]

The following variables were self-reported by the patient: family history of colorectal cancer and other tumors, marital status, occupation at the time of the study, education profile, smoking habit and symptoms prior to surgery, date of onset of symptoms.

Statistical design {#s4_4}
------------------

A descriptive analysis was performed, with measures of central tendency and dispersion for the quantitative variables and frequency distributions for the qualitative ones. Differences were determined by bivariate analysis, segmenting by type of tumour and by time elapsed to first treatment, using the Student t test for quantitative variables and the chi-square test for qualitative ones. Finally, the treatment delay variable was used to perform a multivariate logistic regression analysis, using the variables with a value of p\<0.1, together with the patient\'s age and sex. The level of statistical significance used in these analyses was p\<0.05.
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